Novo Nordisk Gross Margin 1988-2025 | NVO

Current and historical gross margin for Novo Nordisk (NVO) over the last 10 years. The current gross profit margin for Novo Nordisk as of June 30, 2025 is %.
Novo Nordisk Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2025-06-30 $45.48B $38.18B 83.94%
2025-03-31 $43.61B $36.78B 84.34%
2024-12-31 $42.11B $35.65B 84.67%
2024-09-30 $39.37B $33.33B 84.66%
2024-06-30 $37.44B $31.65B 84.53%
2024-03-31 $35.55B $30.09B 84.65%
2023-12-31 $33.72B $28.53B 84.60%
2023-09-30 $30.85B $25.96B 84.16%
2023-06-30 $28.44B $24.00B 84.37%
2023-03-31 $26.41B $22.24B 84.23%
2022-12-31 $25.06B $21.03B 83.92%
2022-09-30 $24.32B $20.47B 84.18%
2022-06-30 $23.81B $19.97B 83.89%
2022-03-31 $23.26B $19.40B 83.38%
2021-12-31 $22.40B $18.64B 83.20%
2021-09-30 $21.64B $17.94B 82.91%
2021-06-30 $20.85B $17.30B 82.98%
2021-03-31 $19.93B $16.57B 83.17%
2020-12-31 $19.45B $16.24B 83.51%
2020-09-30 $19.09B $15.98B 83.69%
2020-06-30 $18.74B $15.68B 83.67%
2020-03-31 $18.84B $15.75B 83.62%
2019-12-31 $18.29B $15.28B 83.54%
2019-09-30 $17.43B $14.61B 83.81%
2019-06-30 $17.25B $14.49B 84.03%
2019-03-31 $17.11B $14.39B 84.10%
2018-12-31 $17.10B $14.41B 84.24%
2018-09-30 $17.61B $14.79B 83.98%
2018-06-30 $17.49B $14.68B 83.95%
2018-03-31 $17.33B $14.57B 84.06%
2017-12-31 $16.97B $14.29B 84.20%
2017-09-30 $16.81B $14.15B 84.21%
2017-06-30 $16.73B $14.16B 84.60%
2017-03-31 $16.67B $14.13B 84.78%
2016-12-31 $16.61B $14.06B 84.62%
2016-09-30 $16.56B $14.05B 84.81%
2016-06-30 $16.43B $13.93B 84.83%
2016-03-31 $16.26B $13.82B 84.94%
2015-12-31 $16.06B $13.65B 85.00%
2015-09-30 $15.99B $13.58B 84.94%
2015-06-30 $15.95B $13.51B 84.68%
2015-03-31 $15.92B $13.37B 84.00%
2014-12-31 $15.83B $13.24B 83.60%
2014-09-30 $15.63B $13.09B 83.73%
2014-06-30 $15.31B $12.75B 83.29%
2014-03-31 $15.08B $12.57B 83.31%
2013-12-31 $14.89B $12.37B 83.08%
2013-09-30 $14.58B $12.14B 83.22%
2013-06-30 $14.27B $11.87B 83.14%
2013-03-31 $13.89B $11.53B 82.97%
2012-12-31 $13.48B $11.16B 82.74%
2012-09-30 $13.04B $10.70B 82.03%
2012-06-30 $12.80B $10.42B 81.44%
2012-03-31 $12.52B $10.14B 80.99%
2011-12-31 $12.27B $9.92B 80.82%
2011-09-30 $12.04B $9.68B 80.44%
2011-06-30 $11.85B $9.61B 81.06%
2011-03-31 $11.48B $9.33B 81.24%
2010-12-31 $11.06B $8.97B 81.17%
2010-09-30 $10.66B $8.63B 80.89%
2010-06-30 $10.24B $8.20B 80.02%
2010-03-31 $9.90B $7.88B 79.64%
2009-12-31 $9.67B $7.72B 79.80%
2009-09-30 $9.31B $7.44B 79.86%
2009-06-30 $9.10B $7.21B 79.27%
2009-03-31 $8.21B $6.27B 76.30%
2008-12-31 $8.12B $6.13B 75.47%
2008-09-30 $8.02B $5.97B 74.43%
2008-06-30 $7.69B $5.70B 74.14%
2008-03-31 $8.11B $6.23B 76.84%
2007-12-31 $7.71B $5.90B 76.61%
2007-09-30 $7.59B $5.84B 77.01%
2007-06-30 $7.24B $5.56B 76.82%
2007-03-31 $6.44B $4.81B 74.70%
2006-12-31 $6.16B $4.55B 73.86%
2006-09-30 $5.81B $4.22B 72.53%
2006-06-30 $5.73B $4.15B 72.42%
2006-03-31 $6.02B $4.46B 74.13%
2005-12-31 $5.86B $4.33B 73.84%
2005-09-30 $5.61B $3.86B 68.88%
2005-06-30 $5.36B $3.65B 68.10%
2005-03-31 $5.13B $3.47B 67.52%
2004-12-31 $4.96B $3.61B 72.87%
2004-09-30 $4.70B $3.66B 77.82%
2004-06-30 $4.46B $3.49B 78.18%
2004-03-31 $4.27B $3.34B 78.12%
2003-12-31 $4.06B $2.92B 72.03%
2003-09-30 $4.13B $3.00B 72.71%
2003-06-30 $3.97B $2.89B 72.88%
2003-03-31 $3.78B $2.78B 73.35%
2002-12-31 $3.54B $2.61B 73.65%
2002-09-30 $3.06B $1.75B 57.19%
2002-06-30 $2.91B $1.83B 62.74%
2002-03-31 $2.80B $1.93B 68.73%
2001-12-31 $2.82B $2.11B 74.80%
2001-09-30 $2.49B $1.86B 74.64%
2001-06-30 $2.43B $1.79B 73.95%
2001-03-31 $2.53B $1.90B 75.03%
2000-12-31 $2.59B $1.96B 75.60%
2000-09-30 $2.95B $2.95B 100.00%
2000-06-30 $3.09B $3.09B 100.00%
2000-03-31 $3.02B $3.02B 100.00%
1999-12-31 $2.96B $2.96B 100.00%
1999-09-30 $2.94B $2.94B 100.00%
1999-06-30 $2.82B $2.82B 100.00%
1999-03-31 $2.75B $2.75B 100.00%
1998-12-31 $2.68B $2.68B 100.00%
1998-09-30 $2.60B $2.60B 100.00%
1998-06-30 $2.65B $2.65B 100.00%
1998-03-31 $2.61B $2.61B 100.00%
1997-12-31 $2.58B $2.58B 100.00%
1997-09-30 $2.60B $2.60B 100.00%
1997-06-30 $2.53B $2.53B 100.00%
1997-03-31 $2.52B $2.52B 100.00%
1996-12-31 $2.56B $2.56B 100.00%
1996-09-30 $2.48B $2.48B 100.00%
1996-06-30 $2.45B $2.45B 100.00%
1996-03-31 $2.48B $2.48B 100.00%
1995-12-31 $2.46B $2.46B 100.00%
1995-09-30 $2.43B $2.43B 100.00%
1995-06-30 $2.36B $2.36B 100.00%
1995-03-31 $2.25B $2.25B 100.00%
1994-12-31 $2.14B $2.14B 100.00%
1994-09-30 $2.04B $2.04B 100.00%
1994-06-30 $1.96B $1.96B 100.00%
1994-03-31 $1.87B $1.87B 100.00%
1993-12-31 $1.84B $1.84B 100.00%
1993-06-30 $1.30B $1.30B 100.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $424.453B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12